As debate rages over drug prices, one of the country’s largest pharmacy benefit managers is touting biosimilars as a way of achieving significant savings over the next five years. Read More »

Issues statement on Congressional hearing "Reviewing the Rising Price of EpiPens." Read More »

CVS Health recently announced that it is preparing to expand its dedication to the prevention of drug abuse in young persons with investments in two programs that will educate on prevention. Read More »

Maxor National Pharmacy Services LLC this week announced that an agreement has been reached for its acquisition of Pharmaceutical Specialties Inc. (PSI). Read More »

Aegerion Pharmaceuticals Inc. has appointed Remi A. Menes as its Chief Commercial Officer (CCO) effective immediately. Read More »

Bexion Pharmaceuticals LLC and the University of Cincinnati Cancer Institute (UCCI) this week announced that the first patient in the Phase I BXQ-350 trial has been dosed. Read More »

Eli Lilly and AstraZeneca recently released a joint announcement revealing that the two companies have received Fast Track designation for the AZD3293 Alzheimer’s disease development program from the U.S. Food and Drug Administration (FDA). Read More »

Zealand Pharma recently announced that Sanofi has submitted updated information for iGlarLixi’s pen delivery device to the U.S. Food and Drug Administration (FDA). Read More »

Eisai Inc. last week announced that new data on FYCOMPA (perampanel) CIII presented at the 12th European Congress on Epileptology (ECE) has shown that adjunctive use of the medication for up to two-and-a-half years has proven to deliver persistent seizure control in patients suffering from primary generalized tonic clonic (PGTC) seizures who have been poorly controlled. Read More »

Pfizer Inc. announced last week that its study to assess the safety, efficiency and immunogenicity of PF-06438179 called REFLECTIONS B537-02 has met its primary endpoint. Read More »

Lycera Corp. recently announced the initiation of its LYC-30937-EC (Enteric Coated) Phase 2 clinical trial for the treatment of patients who are suffering from ulcerative colitis (UC). Read More »

Allergen plc announced last week that it has reached an agreement to acquire Vitae Pharmaceuticals Inc. for $21 per share in cash. Read More »

AcelRx Pharmaceuticals Inc. announced the release of the results of its Phase 3 ARX-04 trial during a conference call and through a webcast on Sept. 15. Read More »

Cumberland Pharmaceuticals has announced that it has initiated a Phase II clinical program involving Portaban. Read More »

The experience of Mylan, the pharmaceutical company under fire for hiking the price of a life-saving allergy medicine, reinforces the importance of competition in the marketplace, one of the country’s largest pharmacy benefit managers said. Read More »

The National Pharmaceutical Council (NPC) has announced that it will host a conference for health care stakeholders to discuss the effect of medical treatment on patient care and how the value of these treatments can be measured. Read More »

Express Scripts last week announced the launch of its Inflammatory Conditions Care Value Program, an all-inclusive method of controlling costs and improving care for individuals who have inflammatory conditions such as rheumatoid arthritis, psoriasis and Crohn’s Disease. Read More »

The trial will focus on idiopathic sudden sensorineural hearing loss (ISSNHL), also called sudden deafness. Read More »

Portola Pharmaceuticals Inc. recently received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) submitted for AndexXa (andexanet alf Read More »

The American Society of Health-System Pharmacists (ASHP) has announced a collaboration with the Institute for Safe Medication Practices (ISMP) for the development of a Medication Safety Certificate Program that will begin in the spring of next year. Read More »